Oncolytic effects of parvovirus H-1 in medulloblastoma are associated with repression of master regulators of early neurogenesis

International Journal of Cancer

Volumn 134, Issue 3, 2014, Pages 703-716

  Lacroix, Jeannine ^a,b   Schlund, Franziska ^a   Leuchs, Barbara ^a   Adolph, Kathrin ^a   Sturm, Dominik ^b   Bender, Sebastian ^a,b   Hielscher, Thomas ^a   Pfister, Stefan M ^a,b   Witt, Olaf ^a,b   Rommelaere, Jean ^a   Schlehofer, Jörg R ^a   Witt, Hendrik ^a,b  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

cellular targets; master regulators of neurogenesis; medulloblastoma; MYC; oncolytic virus; parvovirus H 1PV

Indexed keywords

MYC PROTEIN; OLIGONUCLEOTIDE; ONCOLYTIC PARVOVIRUS; PROTEIN FOXG1B; PROTEIN NFIA; REGULATOR PROTEIN; UNCLASSIFIED DRUG; ZIC1 PROTEIN;

ARTICLE; ASTROCYTE; CANCER CELL CULTURE; CANCER PROGNOSIS; CLINICAL EVALUATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISEASE ASSOCIATION; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG EFFICACY; EMBRYO; GENE EXPRESSION REGULATION; GENE TARGETING; GENOME ANALYSIS; H-1 PARVOVIRUS; HUMAN; HUMAN CELL; INFANT; LD 50; MEDULLOBLASTOMA; MICROARRAY ANALYSIS; NERVOUS SYSTEM DEVELOPMENT; NONHUMAN; ONCOLYTIC VIROTHERAPY; PRIORITY JOURNAL; RISK FACTOR; VIRUS REPLICATION;

EID: 84888008148     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28386     Document Type: Article

References (50)

1. Smith MA, Seibel NL, Altekruse SF, et al. Outcomes for children and adolescents with cancer: challenges for the twenty-first century. J Clin Oncol 2010; 28: 2625-34.
2. Rutkowski S, von HK, Emser A, et al. Survival and prognostic factors of early childhood medulloblastoma: an international meta-analysis. J Clin Oncol 2010; 28: 4961-8.
3. Pfister S, Remke M, Benner A, et al. Outcome prediction in pediatric medulloblastoma based on DNA copy-number aberrations of chromosomes 6q and 17q and the MYC and MYCN loci. J Clin Oncol 2009; 27: 1627-36.
4. Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma comprises four distinct molecular variants. J Clin Oncol 2011; 29: 1408-14.
5. Cho YJ, Tsherniak A, Tamayo P, et al. Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome. J Clin Oncol 2011; 29: 1424-30.
6. Northcott PA, Korshunov A, Pfister SM, et al. The clinical implications of medulloblastoma subgroups. Nat Rev Neurol 2012; 8: 340-51.
7. Hammill AM, Conner J, Cripe TP,. Oncolytic virotherapy reaches adolescence. Pediatr Blood Cancer 2010; 55: 1253-63.
8. Friedman GK, Pressey JG, Reddy AT, et al. Herpes simplex virus oncolytic therapy for pediatric malignancies. Mol Ther 2009; 17: 1125-35.
9. Lacroix J, Witt O, Schlehofer JR, et al. Therapeutic exploitation of onclytic viruses in pediatric oncology. Drugs Future 2010; 35: 1015-1027.
10. Lun XQ, Zhou H, Alain T, et al. Targeting human medulloblastoma: oncolytic virotherapy with myxoma virus is enhanced by rapamycin. Cancer Res 2007; 67: 8818-27.
11. Studebaker AW, Kreofsky CR, Pierson CR, et al. Treatment of medulloblastoma with a modified measles virus. Neuro Oncol 2010; 12: 1034-42.
12. Yu L, Baxter PA, Zhao X, et al. A single intravenous injection of oncolytic picornavirus SVV-001 eliminates medulloblastomas in primary tumor-based orthotopic xenograft mouse models. Neuro Oncol 2011; 13: 14-27.
13. Studebaker AW, Hutzen B, Pierson CR, et al. Oncolytic measles virus prolongs survival in a murine model of cerebral spinal fluid-disseminated medulloblastoma. Neuro Oncol 2012; 14: 459-70.
14. Rommelaere J, Geletneky K, Angelova AL, et al. Oncolytic parvoviruses as cancer therapeutics. Cytokine Growth Factor Rev 2010; 21: 185-95.
15. Geletneky K, Kiprianova I, Ayache A, et al. Regression of advanced rat and human gliomas by local or systemic treatment with oncolytic parvovirus H-1 in rat models. Neuro Oncol 2010; 12: 804-14.
16. Kiprianova I, Thomas N, Ayache A, et al. Regression of glioma in rat models by intranasal application of parvovirus H-1. Clin Cancer Res 2011; 17: 5333-42.
17. Pei Y, Moore CE, Wang J, et al. An animal model of MYC-driven medulloblastoma. Cancer Cell 2012; 21: 155-67.
18. Kawauchi D, Robinson G, Uziel T, et al. A mouse model of the most aggressive subgroup of human medulloblastoma. Cancer Cell 2012; 21: 168-80.
19. Wu X, Northcott PA, Dubuc A, et al. Clonal selection drives genetic divergence of metastatic medulloblastoma. Nature 2012; 482: 529-33.
20. Lacroix J, Leuchs B, Li J, et al. Parvovirus H1 selectively induces cytotoxic effects on human neuroblastoma cells. Int J Cancer 2010; 127: 1230-9.
21. Wrzesinski C, Tesfay L, Salome N, et al. Chimeric and pseudotyped parvoviruses minimize the contamination of recombinant stocks with replication-competent viruses and identify a DNA sequence that restricts parvovirus H-1 in mouse cells. J Virol 2003; 77: 3851-8.
22. El-Andaloussi N, Endele M, Leuchs B, et al. Novel adenovirus-based helper system to support production of recombinant parvovirus. Cancer Gene Ther 2011; 18: 240-9.
23. Bar S, Daeffler L, Rommelaere J, Nuesch JP,. Vesicular egress of non-enveloped lytic parvoviruses depends on gelsolin functioning. PLoS Pathog 2008; 4: e1000126.
24. Witt H, Mack SC, Ryzhova M, et al. Delineation of two clinically and molecularly distinct subgroups of posterior fossa ependymoma. Cancer Cell 2011; 20: 143-57.
25. Huber W, von HA, Sultmann H, et al. Variance stabilization applied to microarray data calibration and to the quantification of differential expression. Bioinformatics 2002; 18 (Suppl 1): S96-S104.
26. Wettenhall JM, Smyth GK,. limmaGUI: a graphical user interface for linear modeling of microarray data. Bioinformatics 2004; 20: 3705-6.
27. Faisst S, Faisst SR, Dupressoir T, et al. Isolation of a fully infectious variant of parvovirus H-1 supplanting the standard strain in human cells. J Virol 1995; 69: 4538-43.
28. Rayet B, Lopez-Guerrero JA, Rommelaere J, et al. Induction of programmed cell death by parvovirus H-1 in U937 cells: connection with the tumor necrosis factor alpha signalling pathway. J Virol 1998; 72: 8893-903.
29. Chen YQ, de FF, Hertoghs J, et al. Selective killing of simian virus 40-transformed human fibroblasts by parvovirus H-1. Cancer Res 1986; 46: 3574-9.
30. Herrero y Calle M, Cornelis JJ, Herold-Mende C, et al. Parvovirus H-1 infection of human glioma cells leads to complete viral replication and efficient cell killing. Int J Cancer 2004; 109: 76-84.
31. Heng C, Lefebvre O, Klein A, et al. Functional role of laminin alpha1 chain during cerebellum development. Cell Adh Migr 2011; 5: 480-9.
32. Li J, Werner E, Hergenhahn M, et al. Expression profiling of human hepatoma cells reveals global repression of genes involved in cell proliferation, growth, and apoptosis upon infection with parvovirus H-1. J Virol 2005; 79: 2274-86.
33. Rommelaere J, Geletneky K, Angelova AL, et al. Oncolytic parvoviruses as cancer therapeutics. Cytokine Growth Factor Rev 2010; 21: 185-95.
34. Ohshima T, Iwama M, Ueno Y, et al. Induction of apoptosis in vitro and in vivo by H-1 parvovirus infection. J Gen Virol 1998; 79: 3067-71.
35. Hatten ME, Roussel MF,. Development and cancer of the cerebellum. Trends Neurosci 2011; 34: 134-42.
36. Noel A, Gutierrez-Fernandez A, Sounni NE, et al. New and paradoxical roles of matrix metalloproteinases in the tumor microenvironment. Front Pharmacol 2012; 3: 140.
37. Kang TH, Kim KT,. VRK3-mediated inactivation of ERK signaling in adult and embryonic rodent tissues. Biochim Biophys Acta 2008; 1783: 49-58.
38. Patterson KI, Brummer T, O'Brien PM, et al. Dual-specificity phosphatases: critical regulators with diverse cellular targets. Biochem J 2009; 418: 475-89.
39. Kobayashi A, Senzaki K, Ozaki S, et al. Runx1 promotes neuronal differentiation in dorsal root ganglion. Mol Cell Neurosci 2012; 49: 23-31.
40. Marchal L, Luxardi G, Thome V, et al. BMP inhibition initiates neural induction via FGF signaling and Zic genes. Proc Natl Acad Sci USA 2009; 106: 17437-42.
41. Blank MC, Grinberg I, Aryee E, et al. Multiple developmental programs are altered by loss of Zic1 and Zic4 to cause Dandy-Walker malformation cerebellar pathogenesis. Development 2011; 138: 1207-16.
42. Gibson P, Tong Y, Robinson G, et al. Subtypes of medulloblastoma have distinct developmental origins. Nature 2010; 468: 1095-9.
43. Adesina AM, Nguyen Y, Mehta V, et al. FOXG1 dysregulation is a frequent event in medulloblastoma. J Neurooncol 2007; 85: 111-22.
44. Dastidar SG, Landrieu PM, D'Mello SR,. FoxG1 promotes the survival of postmitotic neurons. J Neurosci 2011; 31: 402-13.
45. Wang W, Crandall JE, Litwack ED, et al. Targets of the nuclear factor I regulon involved in early and late development of postmitotic cerebellar granule neurons. J Neurosci Res 2010; 88: 258-65.
46. Hasenpusch-Theil K, Magnani D, Amaniti EM, et al. Transcriptional analysis of Gli3 mutants identifies Wnt target genes in the developing hippocampus. Cereb Cortex 2012; 22: 2878-9.
47. Katoh M,. Network of WNT and other regulatory signaling cascades in pluripotent stem cells and cancer stem cells. Curr Pharm Biotechnol 2011; 12: 160-70.
48. Baryawno N, Sveinbjornsson B, Kogner P, et al. Medulloblastoma: a disease with disorganized developmental signaling cascades. Cell Cycle 2010; 9: 2548-54.
49. Salome N, van HB, Duponchel N, et al. Sensitization of transformed rat cells to parvovirus MVMp is restricted to specific oncogenes. Oncogene 1990; 5: 123-30.
50. Rogers HA, Sousa S, Salto C, et al. WNT/beta-catenin pathway activation in Myc immortalised cerebellar progenitor cells inhibits neuronal differentiation and generates tumours resembling medulloblastoma. Br J Cancer 2012; 107: 1144-52.